Sichenzia Ross Ference Kesner LLP Represents XTL Biopharmaceuticals Ltd. in $2.5 Million Registered Direct Offering

Press Release – New York, NY – February 27, 2017 – Sichenzia Ross Ference Kesner LLP announced today that it has represented XTL Biopharmaceuticals, Ltd. (NASDAQ: XTLB) (TASE: XTL.TA), an Israeli clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, in a registered direct offering of 1,000,000 American Depository Shares (“ADSs”) at a price of $2.50 per share and unregistered warrants to purchase 1,000,000 ADSs at an exercise price of $4.10 per ADS for gross proceeds of $2,500,000. Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the offering.  The Sichenzia Ross Ference Kesner LLP team was led by partners Gregory Sichenzia and Avital Even-Shoshan and counsel Cheryll Calaguio.

• About
• Latest Posts

Sichenzia Ross Ference LLP

Sichenzia Ross Ference LLP is a nationally recognized securities and corporate law firm that provides experienced representation in all matters involving the securities industry. Super Lawyers consistently recognizes our attorneys as among the highest rated securities lawyers in the nation. Our attorneys specialize in advising clients on private placements, initial (IPOs) and secondary public offerings, alternative public offerings, preparation of SEC filings and listings on major capital stock exchanges such as the NYSE (New York Stock Exchange), NASDAQ and OTC markets. In addition, our litigation and arbitration attorneys are highly skilled in representing clients from routine lawsuits to complex cases before the SEC, FINRA and other tribunals. We also represent clients in a range of residential and commercial real estate and trusts and estates matters.

Visit SRF's LinkedIn page

Latest posts by Sichenzia Ross Ference LLP (see all)

• Sichenzia Ross Ference LLP Represents Quest Solutions, Inc. in $5 Million Private Placement - April 10, 2019
• Sichenzia Ross Ference LLP Congratulates INmune Bio Inc., on Initial Public Offering - April 10, 2019
• FDA sets first hearing on CBD in May as the agency looks at legalizing the cannabis compound in food and drinks - April 4, 2019